Health Care·Life Sciences Tools & Services·$6.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.16 | N/A | -20.89% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.16 | N/A | -20.89% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions impacting performance. They remain committed to strategic initiatives for future growth.
Management acknowledged the challenges faced this quarter.
They emphasized a focus on long-term growth despite short-term setbacks.
Repligen Corp's earnings report showed a miss on EPS, which contributed to a 1.6% decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's current performance and future outlook. Management's defensive tone suggests they are navigating challenges but remain focused on long-term strategies.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Jul 30, 2018